Abstract
Methyldopa is an antihypertensive agent acting by function as a false transmitter in the central nervous system or in peripheral adrenergic neurons. It is effective in all forms of hypertension, as montherapy or in combination with other antihypertensive agents. Its use is associated with a considerable incidence of adverse effects. Hemodynamically, it reduces peripheral vascular resistance and/or cardiac output.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Manda G, et al: Methyldopa and neural control of circulation in essential hypertension. Am J Cardiol 45:1237, 1980.
Bulpitt CJ, et al: Review of case histories of patients maintained on methyldopa for 10 years or more. In: Zanchetti A (ed) Methyldopa in hypertension. Merck, Sharp and Dohme, Rahway NJ, 1978, p 277.
Weil MH, et al: Alpha-methyldopa for the treatment of hypertension. Circulation 28:165, 1963.
Alcocer L, Aspe J: Hemodynamic, metabolic and ventricular function effects of methyldopa in the treatment of hypertension. In: Zanchetti A (ed) Methyldopa in hypertension. Merck, Sharp and Dohme, Rahway NJ, 1978, p 33.
Sannerstedt R, et al: Hemodynamic effects of methyldopa (Aldomet®) at rest and during exercise in patients with arterial hypertension. Acta Med Scand 171:75, 1962.
Messerli FH, et al: Antiadrenergic therapy: special aspects in hypertension in the elderly. Hypertension [Suppl 2] 3:11–226, 1981.
Sprackling ME, et al: Blood pressure reduction in the elderly: a randomised controlled trial of methyldopa. Br Med J 283:1151, 1981.
Amery A, et al: Antihypertensive therapy in patients above age 60 years (fourth interim report of the European Working Party on High Blood Pressure in the Elderly: EWPHE). Cline Sci Mol Med 55:263, 1978.
Amery A, et al: Glucose intolerance during diuretic therapy: results of trial by the European Working Party on Hypertension in the Elderly. Lancet 1:681, 1978.
Leonetti G, et al: Relationship between the hypotensive and renin-suppressing activities of alpha-methyldopa in hypertensive patients. Am J Cardiol 40:762, 1977.
Weidmann P, et al: Plasma renin and blood pressure during treatment with methyldopa. Am J Cardiol 34:671, 1974.
Heise A, Kroneberg G: Central nervous α-adrenergic receptors and the mode of action of α-methyldopa. Naunyn Schimedebergs Arch Pharmacol 279:285, 1973.
Henning M: Studies on the mode of action of α-methyldopa. Acta Physiol Scand [Suppl] 322:1, 1969.
Henning M, Rubenson A: Evidence that the hypotensive action of methyldopa is mediated by central action of methylnoradrenaline. J Pharm Pharmacol 23:407, 1971.
Messerli FH, et al: Hypertension in the elderly hemodynamics, intravascular volume and endocrine mechanisms. In: Eighth scientific meeting of the International Society of Hypertension, Milan, Italy, 31 May-3 June 1981.
Myhre E, et al: Clinical pharmacokinetics of methyldopa. Clin Pharmacol 7:221, 1982.
Kwan KF, et al: Pharmacokinetics of methyldopa in man. J Pharmacol Exp Ther 198:264, 1976.
Campbell NRC, et al: Platelet phenol sulfotransferase and erythrocyte catechol-O-methyltransferase activities: correlation with methyldopa metablism. Clin Pharmacol Ther 35:55, 1984.
Lawson DH, et al: Adverse reactions to methyldopa with particular reference to hypotension. Am Heart J 96:572, 1978.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1988 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Schneeweiss, A., Schettler, G. (1988). Methyldopa. In: Cardiovascular Drug Therapy in the Elderly. Developments in Cardiovascular Medicine, vol 72. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2063-0_44
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2063-0_44
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9225-8
Online ISBN: 978-1-4613-2063-0
eBook Packages: Springer Book Archive